Redeye provides a research update following the Q1 report published by Newbury yesterday. We make some slight adjustments to our estimates for operational expenditures, investments, and net sales. Accordingly, we update our fair value range with a revised base case valuation of SEK8.5 (SEK9) as we continue to have a positive outlook on the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

Newbury Pharmaceuticals Q1 - Awaiting Commercial Takeoff

© Modular Finance, source Nordic Press Releases